Details for New Drug Application (NDA): 208671
✉ Email this page to a colleague
The generic ingredient in LANSOPRAZOLE is amoxicillin; clarithromycin; lansoprazole. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.
Summary for 208671
| Tradename: | LANSOPRAZOLE |
| Applicant: | Macleods Pharms Ltd |
| Ingredient: | lansoprazole |
| Patents: | 0 |
Pharmacology for NDA: 208671
| Mechanism of Action | Proton Pump Inhibitors |
| Physiological Effect | Inhibition Gastric Acid Secretion |
Medical Subject Heading (MeSH) Categories for 208671
Suppliers and Packaging for NDA: 208671
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LANSOPRAZOLE | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 208671 | ANDA | Macleods Pharmaceuticals Limited | 33342-310 | 33342-310-07 | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-310-07) |
| LANSOPRAZOLE | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 208671 | ANDA | Macleods Pharmaceuticals Limited | 33342-311 | 33342-311-07 | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-311-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | 15MG | ||||
| Approval Date: | Nov 4, 2024 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | 30MG | ||||
| Approval Date: | Nov 4, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
